Jonathan Zalevsky - 18 Aug 2026 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Reporting relationship: Chief R&D Officer
Issuer ticker: NKTR
Reported as of: 18 Aug 2026
Net transaction value: -$13,388
SEC form: 4
Accepted by SEC: 20 Aug 2026, 19:05:31 UTC
Prior SEC filing: 24 Jul 2026
Source filing: View source filing
Reporting owner signature: Elizabeth Zhang, Attorney-in-Fact

Key filing fact

Jonathan Zalevsky filed Form 4 for NEKTAR THERAPEUTICS (NKTR) on 20 Aug 2026.

Key facts

This page summarizes Jonathan Zalevsky's Form 4 filing for NEKTAR THERAPEUTICS (NKTR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Aug 2026, 19:05.

Change

Previous filing in this sequence was filed on 24 Jul 2026.
Current net transaction value: -$13,388.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001789857 Primary reporting owner

Zalevsky Jonathan

Relationship: Chief R&D Officer
Address: C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO
Signature: Elizabeth Zhang, Attorney-in-Fact
Signature date: 20 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NKTR transaction

Common Stock

Sale

Transaction value: $13,388
Shares: -186
Change %: -1.9%
Price: $71.98
Shares after: 9,570
Date: 18 Aug 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.